• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
James Paton

Stay informed with James Paton’s coverage and analysis.

Sanofi will combine its experimental coronavirus vaccine with GlaxoSmithKline Plc’s adjuvant technology, which may allow more doses of a shot to be produced.
HealthSanofi and GlaxoSmithKline are teaming up to develop a coronavirus vaccine
By James Paton, Suzi Ring and BloombergApril 14, 2020
A researcher works on virus replication in order to develop a vaccine against the coronavirus COVID-19, in Belo Horizonte, state of Minas Gerais, Brazil, on March 26, 2020. - The Ministry of Health convened The Technological Vaccine Center of the Federal University of Minas Gerais laboratory to conduct research on the coronavirus COVID-19 in order to diagnose, test and develop a vaccine. (Photo by Douglas MAGNO / AFP) (Photo by DOUGLAS MAGNO/AFP via Getty Images)
HealthA coronavirus vaccine in 18 months? Medical experts say it’s not that simple
By James Paton and BloombergMarch 31, 2020
New British Chief Executive Officer of French pharmaceutical group Sanofi Paul Hudson talks to journalists at Sanofi headquarters in Paris on October 1, 2019. (Photo by ERIC PIERMONT / AFP) (Photo by ERIC PIERMONT/AFP via Getty Images)
HealthWhy Sanofi’s New CEO Is Trading Diabetes Drugs for Cancer Breakthroughs
By James Paton and BloombergDecember 10, 2019
Cancer Drug Company Acquisitions Showcase Pharma Giants Big Push Into Oncology
HealthCancer Drug Company Acquisitions Showcase Pharma Giants Big Push Into Oncology
By Riley Griffin, James Paton and BloombergDecember 9, 2019
Paul Hudson, chief executive officer of Sanofi, gestures as he speaks during a panel session on the sidelines of the China International Import Expo (CIIE) in Shanghai, China, on Tuesday, Nov. 5, 2019. The CIIE -- now in its second year -- is designed to showcase the countrys desire to shift its economy toward consumption by buying more foreign goods. Photographer: Qilai Shen/Bloomberg via Getty Images
FinanceWhy Sanofi Is Buying a U.S. Cancer Biotech for Nearly 3 Times Its Market Value
By James Paton and BloombergDecember 9, 2019
American Vasant Narasimhan, CEO of Swiss pharmaceutical and drug maker Novartis speaks during a conference at the Fortune Global Forum event in Paris on Nov. 18, 2019. (Photo by ERIC PIERMONT / AFP) (Photo by ERIC PIERMONT/AFP via Getty Images)
FinanceNovartis Bets Big on Cholesterol Drug With $9.7 Billion Buyout of Medicines Co.
By James Paton and BloombergNovember 25, 2019
1
  • 1
  • 2
  • 3
3
Most Popular
Economy
'We didn’t see this coming': Wall Street eats its forecasts as stocks sell off globally on fear of AI bubble ahead of SpaceX IPOplaceholder alt text
By Jim EdwardsJune 8, 2026
Success
Gen Zers are arriving at college unable to even read a sentence—professors warn it could lead to a generation of anxious and lonely graduatesplaceholder alt text
By Preston ForeJune 7, 2026
Environment
Trump, who has repeatedly called climate change fake, is now threatening Brazil with tariffs over the deforestation of the Amazonplaceholder alt text
By Sasha RogelbergJune 8, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.